Spots Global Cancer Trial Database for richter's transformation
Every month we try and update this database with for richter's transformation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | NCT01217749 | B-cell Chronic ... Small Lymphocyt... Prolymphocyctic... Richter's Trans... | PCI-32765 ofatumumab | 18 Years - | Pharmacyclics LLC. | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | NCT06043674 | Chronic Lymphoc... Richter's Trans... | Glofitamab Obinutuzumab Polatuzumab Ved... Atezolizumab Tocilizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | NCT00472849 | Richter's Trans... Leukemia | Oxaliplatin Fludarabine Cytarabine Rituximab Pegfilgrastim | 18 Years - | M.D. Anderson Cancer Center | |
| Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | NCT05873712 | Recurrent Trans... Refractory Tran... Transformed Chr... Recurrent Trans... Recurrent Trans... Refractory Tran... Refractory Tran... Refractory Tran... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Leukapheresis Lisocabtagene M... Lymph Node Biop... Positron Emissi... Zanubrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | NCT00452374 | Leukemia | Cytarabine Fludarabine Oxaliplatin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | NCT01217749 | B-cell Chronic ... Small Lymphocyt... Prolymphocyctic... Richter's Trans... | PCI-32765 ofatumumab | 18 Years - | Pharmacyclics LLC. | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | NCT03778073 | B-cell Non Hodg... Richter's Trans... | Cosibelimab Cosibelimab + U... Cosibelimab + U... | 18 Years - | TG Therapeutics, Inc. | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04806035 | CLL SLL Richter's Trans... Indolent Lympho... Follicular Lymp... Marginal Zone L... Aggressive Lymp... DLBCL Mediastinal Lar... MCL | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | NCT04679012 | Richter Syndrom... Chronic Lymphoc... | Polatuzumab Ved... Rituximab Etoposide Prednisone Cyclophosphamid... Hydroxydaunomyc... | 18 Years - | Weill Medical College of Cornell University | |
| 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | NCT00413478 | Chronic Lymphoc... Leukemia | 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
